At Vivere, we recognise that every persons body is different
Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin Blend (12mg) is a combination of peptides that may potentially interact with receptors in the pituitary gland
The lightweight, silky texture absorbs instantly, delivering antioxidant protection to neutralize environmental stressors that accelerate aging
Referral to registered dietitians and behavioral health specialists should be considered for patients with complex needs or previous weight loss failures
Triple Agonist vs Dual Agonist Comparison Contents Key Takeaways Two Compounds, One Manufacturer, Different Receptor Counts Weight Loss: The Numbers Side by Side Mechanism Breakdown: What the Third Receptor Adds Safety: Where the Tradeoffs Appear Evidence Quality: Phase 2 vs Phase 3 Where Each Compound Might Win The Bottom Line Explore Research Peptides Retatrutide 12mg 24.2% body weight lost (Phase 2, 48 wk) vs Tirzepatide 15mg 22.5% body weight lost (Phase 3, 72 wk) 3 vs 2 receptor targets (retatrutide vs tirzepatide) 63% vs 57% reached 20%+ weight loss (highest dose arms) Eli Lilly same manufacturer for both compounds Sources: Retatrutide Phase 2 (NEJM, 2023), SURMOUNT-1 (NEJM, 2022)
Do not wait for routine labs Vision changes, rapid swelling, severe headaches, chest pain, shortness of breath, or allergic symptoms need medical review
